BridgeBio Pharma Long Term Debt 2018-2024 | BBIO
BridgeBio Pharma long term debt from 2018 to 2024. Long term debt can be defined as the sum of all long term debt fields.
BridgeBio Pharma Annual Long Term Debt
(Millions of US $) |
| 2023 |
$1,727 |
| 2022 |
$1,708 |
| 2021 |
$1,704 |
| 2020 |
$476 |
| 2019 |
$92 |
| 2018 |
$55 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Long Term Debt
(Millions of US $) |
| 2024-06-30 |
$1,718 |
| 2024-03-31 |
$1,716 |
| 2023-12-31 |
$1,727 |
| 2023-09-30 |
$1,721 |
| 2023-06-30 |
$1,719 |
| 2023-03-31 |
$1,713 |
| 2022-12-31 |
$1,708 |
| 2022-09-30 |
$1,699 |
| 2022-06-30 |
$1,693 |
| 2022-03-31 |
$1,708 |
| 2021-12-31 |
$1,704 |
| 2021-09-30 |
$1,375 |
| 2021-06-30 |
$1,374 |
| 2021-03-31 |
$1,361 |
| 2020-12-31 |
$476 |
| 2020-09-30 |
$472 |
| 2020-06-30 |
$467 |
| 2020-03-31 |
$461 |
| 2019-12-31 |
$92 |
| 2019-09-30 |
$75 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.791B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
